Rariy Reviews In-Home Infusion Initiative in Oncology
August 2nd 2021Chevon M. Rariy, MD, discusses how the implementation of telehealth during the COVID-19 pandemic shed light on the need for increased access to care for patients with cancer, as well as the potential benefits in-home infusions could offer to patients receiving chemotherapy.
Read More
Analyzing the Advancing Applications for Next-Generation Sequencing in Lung Cancer
July 26th 2021Drs Brown and Husain discuss the current and future applications of next-generation sequencing in lung cancer, the role of tissue-based testing in light of the growing role for liquid-based testing, and some of the emerging technologies that could overcome current barriers to biomarker testing.
Read More
Jabbour on Tailoring Treatment With TKIs in CML and Ph+ ALL
July 19th 2021Dr. Jabbour discusses the optimal use of ponatinib in chronic myeloid leukemia and data from the 2021 ASCO Annual Meeting with the combination of blinatumomab and ponatinib in Ph-positive acute lymphoblastic leukemia.
Read More
Halmos Highlights Effort Exploring COVID-19 Vaccines in Patients With Cancer
June 24th 2021Dr. Halmos discusses the data from a study examining seroconversion rates following COVID-19 vaccination among patients with cancer and underscores the need for novel vaccination or passive immunization strategies for immunosuppressed cohorts.
Read More
Matsen Reflects on Changes to Breast Cancer Surgery During COVID-19
June 21st 2021Dr. Masten reflects on the main challenges that arose during the COVID-19 lockdown with regard to surgery in patients with breast cancer, the steps that were taken as the lockdown started to lift, and the changes that have been made with regard to managing patients around the time of surgery and in the operating room.
Read More
George Gives Take on Optimal Sequencing, Strategies in Pancreatic Cancer Pipeline
June 17th 2021Dr. George discusses treatment considerations in the first-line setting of metastatic pancreatic cancer, signs that may indicate disease progression and the need for second-line therapy, and investigational agents in the pipeline.
Read More
Pant Projects an Expanding Role for Targeted Therapy in Pancreatic Cancer
June 14th 2021Dr. Pant discusses the current role for germline and somatic testing in pancreatic cancer, examines the research landscape with PARP inhibitors, KRAS inhibitors, and other targeted agents, and shares his hope for the future of drug development in the field.
Read More
FDA Approval Insights: Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma
June 7th 2021Dr. Munshi discusses the significance of the FDA approval of ide-cel in relapsed/refractory multiple myeloma, data from the KarMMa trial, which served as the basis for the approval, and next steps for CAR T-cell therapy in the field.
Read More
Landgren Breaks Down the Benefit of Novel Quadruplet in Newly Diagnosed Myeloma
May 31st 2021Dr. Landgren discusses the potential of a quadruplet regimen comprised of carfilzomib, lenalidomide, dexamethasone, and daratumumab in the treatment of patients with newly diagnosed multiple myeloma.
Read More